What Аспикард Treats: Main Uses and Benefits

This medication is generally considered relevant for managing conditions where preventative support against blood clot formation is necessary.

The medication is commonly used to address ongoing cardiovascular risk in patients with a history of major vascular events like a heart attack, an ischemic stroke, or a transient ischemic attack. It is also applied in acute clinical situations characterized by sudden, severe ischemic chest discomfort, such as unstable angina or suspected acute myocardial infarction. Additionally, its continuous use is relevant following vascular interventions, including coronary stenting and bypass graft surgery.

“The continuous use of this medication may help patients cope more steadily with symptom fluctuations associated with chronic vascular conditions.”

The primary patient benefit is long-term preventative support, and it contributes to reducing the overall burden of recurrent serious events. It is considered relevant in acute episodes to support the management of the critical situation and assists with symptomatic management.

Quick Fact: Support in Acute Ischemic Discomfort
Primary Use Context	Secondary prevention after major vascular events.
Acute Scenario Relevance	Supports management during suspected myocardial infarction.
Post-Intervention Benefit	Assists with maintaining the long-term patency of treated vessels.
Symptom Type Managed	Ischemic symptoms related to blood flow constriction.

Eligibility Map: Who can and cannot use Аспикард — Official Regulatory Information

Eligibility scope

Classification	Populations Covered
Allowed	Adults for cardiovascular prophylaxis (secondary prevention).
Not Recommended	First and second trimesters of pregnancy; continuous high-dose therapy while breastfeeding.
Contraindicated	Patients with known hypersensitivity to salicylates or NSAIDs; active peptic ulceration; history of GI bleeding; haemophilia; severe hepatic/renal impairment; and severe uncontrolled cardiac failure.

Age-related Eligibility Rules

• Children and Adolescents: Contraindicated in those generally under 16 years, particularly with viral infections, due to the risk of Reye's syndrome.
• Older Adults (Geriatric): Use requires caution due to a documented increased risk of bleeding events.

Condition-specific Eligibility Rules

• Organ Impairment: Severe hepatic impairment and severe renal impairment are formal contraindications. Use in patients with moderate impairment of either organ is restricted to caution.
• Comorbidities: Use requires caution in patients with uncontrolled hypertension, a history of gout, or respiratory conditions like asthma and nasal polyps.

Pregnancy and Lactation Eligibility Status

The medicine is strictly contraindicated throughout the third trimester of pregnancy. Use is generally not recommended in the first and second trimesters. During lactation, use is not recommended during continuous high-dose therapy, as per regulatory documentation.

The official regulatory profile for Acetylsalicylic Acid (ASA), the active ingredient in Аспикард, defines several clinically significant drug-drug and drug-substance interactions, primarily structured around enhanced bleeding risk and interference with elimination pathways.

Interaction Category	Specific Substance Examples
Formal Contraindications	Methotrexate (at doses ge 15 mg/week)
	Oral Anticoagulants (with history of GI ulcers)
Enhanced Bleeding/GI Risk	Other NSAIDs, Antiplatelet Agents, SSRIs, Alcohol
Timing/Elimination Rules	Methotrexate, Ibuprofen, Uricosurics

Co-administration with Methotrexate at or above 15 mg per week is formally contraindicated because Acetylsalicylic Acid is documented to reduce its renal clearance, which can lead to enhanced toxicity. This elimination interference risk is considered greatest in patients with pre-existing renal impairment.

Pharmacodynamic interactions with other Antiplatelet Agents, Oral Anticoagulants, and SSRIs are documented to result in an increased risk of haemorrhage. Similarly, the combination with Alcohol and other NSAIDs is specified as increasing the risk of gastrointestinal ulcers and bleeding.

Regulatory labels define a separation requirement for co-administration with Ibuprofen; the immediate-release form of ASA must be administered at least 30 minutes after or 8 hours before Ibuprofen to prevent interference with the antiplatelet effect. Furthermore, the efficacy of Diuretics and certain Antihypertensive agents may be reduced when used concurrently.

How Аспикард Works

The mechanism of action of Аспикард centers on its ability to permanently alter the function of platelets, the blood components responsible for initiating clot formation. This effect is achieved through two primary, interrelated mechanistic domains.

---

Irreversible Enzyme Inhibition in Platelets

This domain addresses the drug’s fundamental interaction with its molecular target. The active ingredient Acetylsalicylic Acid (ASA) acts as an irreversible inhibitor of the enzyme Cyclooxygenase-1 (COX-1), which is present in circulating platelets. By forming a stable, covalent bond with the enzyme, ASA permanently deactivates it. Since platelets are anuclear and unable to synthesize new enzymes, this action creates a functional deficit that persists for the lifespan of the affected platelet. This mechanism creates a sustained functional defect in the platelet.

---

Suppression of Pro-Thrombotic Signaling ( TXA2 Pathway)

The second domain outlines the resulting pathway consequence. The permanent inhibition of COX-1 prevents the metabolism of arachidonic acid, thereby halting the synthesis of Thromboxane A2 ( TXA2). TXA2 is a key signaling molecule that promotes platelet activation and aggregation. By eliminating this key signal, the medicine diminishes platelet aggregability and subsequent thrombus formation. This targeted physiological adjustment contributes to a systemic antithrombotic state in the vasculature.

How to Use Аспикард

Аспикард, based on Acetylsalicylic Acid (ASA), is administered via the oral route. The general principles of its use are defined by the clinical context: a continuous, long-term regimen for prevention versus a single, rapid administration for acute events.

---

Long-Term Administration and Handling

For long-term cardiovascular prophylaxis, the protocol dictates a once-daily maintenance dose typically ranging from 75 mg to 162 mg. This regimen is generally prescribed for an indefinite duration. The medicine may be taken with or without food; however, maintaining a consistent daily timing is a common practice.

When using the common enteric-coated tablet, it must be swallowed whole and not crushed, cut, or chewed. This instruction preserves the tablet's delayed-release properties, which are intended to protect the stomach lining.

---

Acute Use and Population Constraints

When a rapid onset of action is required, such as during a suspected acute coronary event, the instruction is to administer a single, higher loading dose of 160 mg to 325 mg using an immediate-release preparation. The enteric-coated form is unsuitable for this acute scenario due to its delayed absorption.

Specific usage constraints apply based on the patient's physiological status: the use of this medicine is generally avoided in cases of severe hepatic impairment or severe renal failure.

Recent Clinical Evidence for Low-Dose Aspirin

Clinical research concerning the use of low-dose aspirin (typically 75-100 mg daily), the active substance in Аспикард, continues to refine its role in the prevention of cardiovascular events.

Secondary Prevention

For secondary prevention—in patients with established cardiovascular disease (CVD), such as a prior heart attack or stroke—the benefits of daily low-dose aspirin are well-established. Extensive meta-analyses consistently support its use to reduce the risk of subsequent major adverse cardiovascular events (MACE), including non-fatal heart attack, non-fatal stroke, and cardiovascular death.

Primary Prevention

The role of aspirin for primary prevention—in individuals without a prior history of CVD—is more complex and has been the subject of recent large-scale trials. These studies indicate that the benefits of preventing MACE in the general population at moderate risk are modest and are often counterbalanced by an increased risk of major bleeding, particularly gastrointestinal and intracranial bleeding. This has led to updated guidelines generally recommending against routine initiation of aspirin for primary prevention in adults over 60 years of age, and in those with an elevated risk of bleeding at any age. For adults aged 40 to 59 years with a higher (10% or greater) 10-year CVD risk and low bleeding risk, therapy should be considered on an individualized, patient-physician basis.

Enteric Coating

The formulation of low-dose aspirin, such as the enteric-coated (EC) form, aims to reduce gastric irritation by delaying dissolution until the tablet reaches the small intestine. However, clinical data on EC aspirin's effectiveness in reducing gastrointestinal (GI) bleeding compared to uncoated aspirin are inconsistent, with some evidence suggesting that the coating does not eliminate the risk of GI injury, especially in the long term. Furthermore, some studies have noted that the enteric coating may, in some individuals, lead to reduced or variable absorption, which could potentially diminish the intended antiplatelet effect.

Common questions about Аспикард (FAQ)

Q: Why is Аспикард sometimes called 'baby aspirin'?

The unofficial term “baby aspirin” refers to the specific, lowest dosage strength of the active ingredient, Acetylsalicylic Acid (ASA), which is typically 75 mg or 81 mg. Regulatory information indicates that this low dose is the one generally used for long-term cardiovascular prevention in adults. This explains why the term refers to the dosage strength, and not to the population for whom it is officially intended.

Q: If I miss a dose of Аспикард, what should I do?

Official product information suggests that if a dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for your next scheduled dose, it is advised to skip the missed dose entirely and resume your regular daily schedule. Regulatory sources strictly caution against taking a double dose to make up for a missed one.

Q: What happens if I accidentally take two doses of Аспикард close together?

Official prescribing information strongly cautions against taking more than the dose recommended by a healthcare provider. Regulatory documents state that exceeding the daily limit may increase the risk of documented side effects, particularly those related to toxicity. Reported side effects associated with excessive doses include issues like tinnitus (a persistent ringing in the ears) or other hearing disturbances.

Q: Are there any known interactions between Аспикард and herbal supplements?

While regulatory documents do not provide warnings for every single herbal product, specific caution is advised for non-prescription products with anti-clotting potential. Official safety information indicates that combining the medicine with supplements such as omega-3 fatty acids (fish oil) may require careful assessment, as this combination may be associated with an additive risk of bleeding.

Q: How long after stopping Аспикард does its effect last in the body?

The active substance in Аспикард irreversibly inhibits the clotting function of platelets, the blood cells involved in forming clots. Since these cells cannot repair themselves, the antiplatelet effect is sustained for the lifespan of the affected platelet. Official pharmacological data indicates this continuous effect typically lasts for about 7 to 10 days.

Q: Is there any risk associated with taking Аспикард before surgery?

Official safety information acknowledges that the use of this medicine carries an inherent risk of increased bleeding, which is a key concern when planning any surgical procedure. Consensus guidelines often recommend that patients receiving the drug for heart disease prevention (secondary prevention) usually continue treatment. However, the decision to continue or temporarily stop the drug before surgery is determined by the patient’s healthcare team after weighing the risks.

Q: What happens if I stop taking Аспикард suddenly?

Official health guidelines and regulatory documents warn that abrupt discontinuation, particularly when the medicine is used for the secondary prevention of a heart issue, is associated with a temporary increased risk of forming blood clots. This potential increase in thrombotic events is described as possibly leading to serious cardiovascular events, such as a heart attack or stroke.

Q: Can I take Аспикард if I have diabetes?

Official guidelines and research indicate that patients with Type 2 diabetes who also have an elevated risk for cardiovascular disease may be considered for this low-dose therapy. Use of the medicine in people with diabetes is determined by a healthcare professional following an assessment of their specific risk profile.

Q: Are there specific symptoms that mean I need to stop taking Аспикард immediately?

Official regulatory guidance advises seeking immediate medical attention if signs of a serious adverse event or internal bleeding occur. Symptoms that have been identified as requiring immediate medical assessment include sudden onset of chest pain, shortness of breath, sudden weakness, or slurred speech. These symptoms require prompt medical review.

Q: Can I take multivitamins or fish oil supplements with Аспикард?

Standard multivitamins are not generally associated with specific regulatory warnings regarding this medicine. However, official safety cautions are noted for supplements with anti-clotting potential, such as omega-3 fatty acids (fish oil). It is important that the use of any such supplement be discussed with a healthcare provider due to the potential for an additive effect that may increase the risk of bleeding.

How to Store and Dispose of Аспикард?

Regulatory documentation strictly defines the required storage environment and disposal protocols for this medication.

Official Storage Requirements

Condition	Requirement Defined in Regulatory Sources
Temperature	Store at controlled room temperature, typically between 15mathrmC and 30mathrmC.
Environment	Must be protected from heat and moisture and kept from freezing.
Integrity	Keep the product tightly closed in the original container.
Stability Alert	Discard immediately if the tablets develop a strong vinegar odor, which signals degradation.
Safety	The product must be stored out of the sight and reach of children and pets.

Official Disposal Protocol

Unused or expired medication should be taken to a medication take-back program as the primary method of disposal. If a take-back program is unavailable, the product must be prepared for household trash by mixing it with an unappealing substance (like dirt or coffee grounds) and sealing it in a bag or container. This protocol is intended to prevent environmental contamination, as the active substance is harmful to aquatic life.